RT Journal Article
T1 Study of the effectiveness of first-line treatment in renal cell carcinoma.
A1 Sastre-Heres, Alejandro J
A1 Alaguero Calero, Miguel
A1 Ruiz-Sánchez, Daniel
A1 Iglesias García, María Teresa
A1 Calleja Hernandez, Miguel Angel
A1 Martínez Martínez, Fernando
A1 Peña-Díaz, Jaime
K1 Renal cell cancer
K1 Effectiveness
K1 Sunitinib
K1 Temsirolimus
K1 Prognosis
K1 Resultado del Tratamiento
K1 Antineoplásicos
K1 Inhibidores de la Angiogénesis
K1 Carcinoma de Células Renales
K1 Pronóstico
K1 Supervivencia
K1 Estudio Observacional
AB The emergence of novel drugs corresponds with the determination of the effectiveness of the current treatments used in clinical practice. A retrospective observational study was conducted to evaluate the effectiveness of first-line treatments and to test the influence of the prognostic factors established using the Memorial Sloan-Kettering Cancer Center (MSKCC) and the analysis of Mekhail's study for two or more metastatic sites. The primary endpoints were median progression-free survival (mPFS) and median overall survival (mOS) times. A total of 65 patients were enrolled and the mPFS and mOS of the patients treated with sunitinib (n=51) were 9.0 and 20.1 months, respectively, and for the patients treated with temsirolimus (n=14) these were 3.0 and 6.2 months, respectively. In the poor-prognosis (PP) group, a difference of 1.2 months (P=0.049) was found in mPFS depending on the first-line treatment. A difference of 4.1 months (P=0.023) was also found in mPFS when classified by histology (clear verses non-clear cell) in the sunitinib-treatment group. When stratified by the prognostic group, differences of >7 months (P<0.001) were found between the groups. Therefore, it was concluded that the effectiveness of the treatments was reduced compared to previous studies and differences were found in the PP group when classified by first-line drug and histology. Additionally, the influence of prognostic factors on OS and the value of stratifying patients using these factors have been confirmed.
PB Spandidos Publications
SN 2049-9450
YR 2014
FD 2014-11
LK http://hdl.handle.net/10668/1933
UL http://hdl.handle.net/10668/1933
LA en
NO Sastre-Heres AJ, Calero MA, Ruiz-Sánchez D, García MT, Hernandez MA, Martínez FM, et al. Study of the effectiveness of first-line treatment in renal cell carcinoma. Mol Clin Oncol. 2014; 2(6):1167-1171
NO JOURNAL ARTICLE;
DS RISalud
RD Apr 12, 2025